Attralus Has Been Granted U.S. FDA Fast Track Designation for Zamubafusp Alfa (AT-02) for the Treatment of AL Amyloidosis Aug 12, 2026
Attralus Therapeutic Zamubafusp Alfa (AT-02) Receives U.S. FDA Orphan Drug Designation for the Treatment of AL Amyloidosis Jun 4, 2026
Bayer to expand into molecular imaging with acquisition of innovative pan-amyloid radiotracers from Attralus Jan 12, 2026
Attralus To Present Phase 1/2 Data on Its Pan Amyloid Depleter at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition Nov 4, 2025
